Hepatic Carcinoma Clinical Trial
Official title:
A Prospective Study of Ga-68 Dolacga Scintigraphy to Evaluate Liver Reserve Function in Patients With Hepatocellular Carcinoma Before and After Proton Therapy
This is a single-center, prospective, open-labeled, single-arm, interventional study to evaluate liver reserve and tumor response using Ga-68 Dolacga positron emission tomography and the safety of the investigational product in patients with hepatocellular carcinoma before and after proton therapy.
This is a single-center, prospective, open-labeled, single-arm, interventional study to evaluate liver reserve and tumor response using Ga-68 Dolacga positron emission tomography and the safety of the investigational product in patients with hepatocellular carcinoma before and after proton therapy. This trial will enroll 10 eligible subjects. All subjects will provide informed consent before any study procedures are performed. Screening procedures (visit 1) will occur within 21 days prior to imaging visit (visit 2) and will include: inclusion/exclusion criteria check, pregnancy test (if applicable), vital signs, laboratory tests, electrocardiogram (ECG) and establishment of baseline characteristics. Primovist MRI will occur within 14 days prior to imaging visit (visit 2) and 1 week after imaging visit (visit 4), and will be performed according to standard procedure of study site. The baseline characteristics include medical/medication history, fibrosis index, Child-Pugh score and classification, MELD score, liver oncology diagnosis, tumor size, preoperative treatments (portal vein embolization, transarterial chemoembolization, transarterial embolization or biliary drainage), existence of thrombosis (portal vein thrombosis or hepatic vein thrombosis). The liver tissue fibrosis index FIB-4 will be measured to assess the morphological changes. During the imaging session (visit 2, Day 1; visit 4, Day 84±3), a catheter will be placed for intravenous (IV) administration of Ga-68 Dolacga. Subjects will receive an iv bolus injection of 2.0±1.0 mCi Ga-68 Dolacga. A PET/CT scan will be kinetically performed for 60 minutes immediately after IV injection. The measurement of liver reserve is the primary endpoints of this study and measurement will be evaluated by Ga-68 Dolacga PET. The measurement of liver reserve will be performed at visit 2 and visit 4 of this study for all subjects. Adverse events will be continuously monitored during the imaging session. Two follow-up visits (visit 3 at Day 7±2 and visit 5 at Day 91±2) will be conducted to confirm subject well-being and to collect information about any new adverse events (if any). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03253250 -
The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
|
Phase 4 | |
| Terminated |
NCT01760616 -
Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
|
Phase 4 | |
| Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
| Not yet recruiting |
NCT03149523 -
Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors
|
N/A | |
| Recruiting |
NCT05009550 -
ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation
|
N/A | |
| Recruiting |
NCT06342414 -
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
|
||
| Recruiting |
NCT03132740 -
Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma
|
||
| Completed |
NCT03164382 -
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
|
Phase 3 | |
| Completed |
NCT03572582 -
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT04266548 -
Arterial Base Fluorescence Segmental Positive Staining
|
N/A | |
| Recruiting |
NCT03013712 -
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01350726 -
Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan
|
N/A | |
| Completed |
NCT06245798 -
Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
|
||
| Recruiting |
NCT06311396 -
Development of a Neuronal Microscope
|
N/A | |
| Recruiting |
NCT04220944 -
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
|
Phase 1 | |
| Completed |
NCT02352935 -
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
|
N/A | |
| Completed |
NCT02332551 -
Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder
|
N/A | |
| Completed |
NCT02834780 -
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
| Completed |
NCT05007548 -
to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve
|
Phase 2 | |
| Completed |
NCT03163186 -
Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).
|
N/A |